Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Multicenter Randomized Controlled Trial Of The Management Of Unresectable Malignant Mesothelioma Proposed By The British Thoracic Society And The British Medical Research Council.

D. Girling, M. Muers, W. Qian, D. Lobban
Published 2002 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Malignant mesothelioma is almost invariably fatal. The incidence of the disease is rising rapidly in many countries, and there is no generally accepted standard treatment for patients with unresectable disease. According to current British Thoracic Society (BTS) guidelines, patients should be treated with active symptom control (ASC), involving (1) regular follow-up in a specialist clinic; (2) structured assessments of physical, psychological and social problems with appropriate action; (3) rapid involvement of additional specialists; and (4) parallel nursing support. Although many nonrandomized studies have reported tumor responses to anticancer chemotherapy, few have studied palliation and it is not known whether chemotherapy prolongs survival or provides clinically worthwhile palliation with acceptable toxicity when given in addition to ASC. We therefore plan to conduct a multicenter randomized controlled trial comparing (1) ASC alone, (2) ASC plus mitomycin vinblastine and cisplatin (MVP), and (3) ASC plus vinorelbine (N; Navelbine, Pierre Fabre Oncology, Winchester, UK). We chose these chemotherapy regimens because they have been shown in nonrandomized studies to provide good symptom control as recorded by patients. The outcome measures are overall survival, palliation of symptoms, performance status, analgesic usage, toxicity, quality of life, tumor response, and recurrence/progression-free survival. In a preliminary feasibility study, we are assessing the acceptability of the trial design to patients and the suitability of two standard quality-of-life instruments in mesothelioma. Data will help us to decide the final details of the large multicenter trial.
This paper references
10.1136/thorax.55.9.725a
Malignant mesothelioma: predictors of prognosis and clinical trials
J. Steele (2000)
10.1200/JCO.1994.12.6.1156
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
V. Rusch (1994)
10.1136/thorax.56.4.250
Statement on malignant mesothelioma in the United Kingdom
T. British (2001)
10.1038/sj.bjc.6690105
The European mesothelioma epidemic
J. Peto (1999)
10.1016/S0140-6736(95)90462-X
Continuing increase in mesothelioma mortality in Britain
J. Peto (1995)
10.1093/jnci/92.3.205
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
EORTC QLQ-C30 Scoring Manual
P. Fayers (1995)
10.1200/JCO.1993.11.6.1172
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.
D. Sugarbaker (1993)
10.1038/bjc.1990.434
Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist.
J. de Haes (1990)
10.1080/09553008014551861
WHO Handbook for Reporting Results of Cancer Treatment
R. Hunter (1980)
10.1200/JCO.2000.18.23.3912
Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
J. Steele (2000)
10.1038/sj.bjc.6690085
Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise
R. Stephens (1999)
10.1378/CHEST.113.1_SUPPLEMENT.66S
A review of chemotherapy trials for malignant mesothelioma.
C. Ryan (1998)
10.1200/JCO.1999.17.1.25
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
10.1200/JCO.1993.11.8.1559
Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.
A. Chahinian (1993)
10.1038/sj.bjc.6600118
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
J. van Haarst (2002)
10.1016/S0169-5002(00)80056-2
Multicenter phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma (MPM)
J. Haarst (2000)
10.1023/A:1008236010868
Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma.
George W. Middleton (1998)
10.1200/JCO.1987.5.1.86
Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study.
M. Samson (1987)
Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma.
P. Sørensen (1985)



This paper is referenced by
10.1136/thorax.58.9.809
Lung cancer • 8: Management of malignant mesothelioma
C. Parker (2003)
Angiogenesis, cyclooxygenase-2 and matrix metalloproteinases in malignant mesothelioma
J. Edwards (2003)
10.1007/0-387-31056-8_38
Therapy for malignant pleural mesothelioma
H. Pass (2006)
10.1038/modpathol.3800067
Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers
J. Trupiano (2004)
10.1093/ANNONC/MDH356
The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.
E. Andreopoulou (2004)
10.4081/CDR.2011.E13
Asbestos-the Silent Killer: a review of screening and diagnostic imaging of asbestos related lung disease
Ali Khan (2011)
10.1177/030089160509100104
Epirubicin and Gemcitabine as First-Line Treatment in Malignant Pleural Mesothelioma
L. Portalone (2005)
10.1007/S00420-003-0498-6
Factors influencing long-term survival in mesothelioma patients—results of the German mesothelioma register
V. Neumann (2004)
10.1016/J.HOC.2005.09.010
An overview of chemotherapy for mesothelioma.
L. Krug (2005)
10.1016/S0093-7754(02)70044-4
Emerging insights into the biology and therapy of malignant mesothelioma.
N. Vogelzang (2002)
10.1016/j.nedt.2014.02.007
Impact of a nursing education program about caring for patients in Japan with malignant pleural mesothelioma on nurses' knowledge, difficulties and attitude: a randomized control trial.
Yasuko Nagamatsu (2014)
10.3816/CLC.2003.N.023
Chemotherapy for malignant pleural mesothelioma.
P. Jänne (2003)
10.1136/BMJ.328.7434.237
Radical surgery for mesothelioma
T. Treasure (2004)
10.1053/J.SEMINONCOL.2005.02.010
New agents in the management of advanced mesothelioma.
N. Vogelzang (2005)
10.1016/J.LUNGCAN.2004.04.003
Second Heidelberg Thoracic Oncology Symposium on the Diagnosis and Treatment of Pleural Mesothelioma--introduction.
N. Thatcher (2004)
10.3892/OR.11.3.559
Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review).
T. Boulikas (2004)
10.1007/0-387-28274-2_39
First-Line Chemotherapy for Malignant Pleural Mesothelioma
P. Jänne (2005)
10.1016/B978-0-443-06861-4.50069-1
THORACIC SURGERY: A PALLIATIVE CARE SPECIALTY
B. Nelems (2008)
10.1136/BMJ.328.7434.238
Pandemic risks from bird flu
W. Barclay (2004)
10.1117/12.571998
Use of OCT to study tumor cell growth in 3D membranes
Y. Yang (2004)
10.1016/S0014-2999(03)01907-1
Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines.
A. de Cupis (2003)
Semantic Scholar Logo Some data provided by SemanticScholar